Last Updated on December 31, 2023 by The Health Master
The Directorate General of Trade Remedies (DGTR) has initiated an anti-dumping investigation concerning imports of vitamin-A palmitate originating in China, the European Union and Switzerland, based on a petition filed by Piramal Pharma Ltd.
The anti-dumping duty regulators had imposed duty on imports of vitamin-A palmitate from China and Switzerland in the past also.
The Directorate has called for the filing of relevant information through email from the known exporters in the subject countries, their governments through their embassies in India, the importers and users in India known to be concerned with the subject goods, and the domestic industry within 30 days from the date of receipt of the notice.
The investigation will be conducted on vitamin-A palmitate, covering following in all its strengths and forms, with or without stabilization:
- Vitamin A palmitate 1.7 MIU/Gm
- Vitamin A palmitate 1.0 MIU/Gm
Though differing only in concentration, these are product sub-types with the same end uses and are also technically and commercially substitutable.
The petitioner has submitted that the PUC is used in a wide variety of intermediate products falling under various sectors, including food, cosmetics, and pharmaceutical industries.
However, the scope of the product under consideration (PUC) does not cover vitamin-A palmitate, 1.6 MIU/Gm which is used for animal consumption and has different end-uses compared to the PUC.
The company said that the goods produced by the domestic industry are comparable to the goods imported from China, the European Union, and Switzerland in terms of technical specifications, manufacturing processes and technology, functions and uses, and tariff classification. The applicant has claimed that the two are technically and commercially substitutable.
Piramal Pharma Ltd filed the application claiming that it is the sole producer of the subject goods in the country and it has two facilities manufacturing these products at Mahad, in Maharashtra and at Digwal, in Telangana.
For the purpose of investigation, the Authority has considered 12 months:
- From July 1, 2021 to June 30, 2022 as the period of investigation (PoI) and the period of injury covers the period
- From April 1, 2018 to March 31, 2019,
- From April 1, 2019 to March 31, 2020,
- From April 1, 2020 to June 30, 2021 and the PoI.
Piramal Pharma has submitted data from April, 2021 to June 2021 so that there is no gap in the injury analysis period.
The company proposed to construct the normal value for China on the basis of the best available information, since they were not able to obtain any reliable information for the purpose of the normal value on the product from the country, having regard to the cost of production duly adjusted, and with a reasonable margin.
Similarly, it claimed that no reasonable, authentic transaction selling price was available in the domestic markets of the European Union and Switzerland, and it was also unable to gather data on the representative prices of the particular goods when exported from these locations.
It has proposed to construct the normal value for the European Union and Switzerland on the basis of estimates of the cost of production in these countries considering the cost of the domestic industry duly adjusted after addition for selling, general and administrative expenses and reasonable profits.
The authority accepted these claims with respect to the determination of the normal value for China, the European Union, and Switzerland, for the purpose of the initiation of the investigation.
CDSCO panel gives nod for BE study of Tadalafil Oral Jelly
List of approved New Drugs Updated
No need to recall, re-label the drug for price revision if…….:NPPA
ICMR releases Antimicrobial guidelines 2022
CDSCO Panel gives nod Clinical Trial for this Anticancer Drug
USFDA gives final approval for this Insomnia drug
Drug recall: 4 lots of Quinapril Tablets recalled due to this reason
IPC launches 10 new impurities standards
Registration for sale of Medical Devices: Procedure and conditions
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
